Bright-Field Head Identification | However, in addition to informative feature selection and the curation of a representative training set , the performance of SVM classification models is subject to several parameters associated with the model itself and its kernel function [34, 48]. |
Bright-Field Head Identification | Thus, to ensure good performance of the final SVM model, we first optimize model parameters based on fivefold cross-validation on the training set (Fig 3A and 3B, Materials and Methods). |
Bright-Field Head Identification | To visualize feature and classifier performance, we use Fisher’s linear discriminant analysis to linearly project the 14 layer 1 features of the training set onto two dimensions that show maximum separation between grinder and background particles (Fig 3C). |
Discussion | In both layers of classification, we adopt a supervised learning approach that depends upon human annotation of training sets of data. |
Discussion | Overall, our proposed methodology provides a pipeline that streamlines and formalizes the image processing steps after the annotation of a training set . |
Identification of Fluorescently Labeled Cells | Using this feature set, we optimize and train a layer 1 SVM classifier using a manually annotated training set (n = 218) (S4A Fig, Materials and Methods) and show that it is sufficient for identifying cellular regions with relatively high sensitivity and specificity (Fig 5D and 84A Fig). |
Identification of Fluorescently Labeled Cells | To construct a new problem-specific layer 2 classifier based on relationships within these tetrad candidates, we optimize and train a SVM model based on a manually annotated training set (n = 324) (84C Fig). |
Application in combinatorial drug discovery | They are then used as a training set to produce a predictor hy. |
E" o \l | Finally, all predicted antimicrobial peptides are significantly different from those of the training set , sharing only 40% similarity with their most similar peptide in the CAMPs dataset. |
Improving the bioactivity of peptides | For the CAMPS dataset, the proposed approach predicted that peptide WWKWWKRLRRLFLLV should have an antibacterial potency of 1.09, a logarithmic improvement of 0.266 over the best peptide in the training set (GWRLIKKILRVFKGL, 0.824), and a substantial improvement over the average potency of that dataset (average of 0.39). |
Improving the bioactivity of peptides | On the BPPs dataset, the proposed approach predicted that the pentapeptide IEWAK should have an activity of 2.195, slightly less than the best peptide of the training set (VEWAK, 2.73, predicted as 2.192). |
Improving the bioactivity of peptides | Hence, our proposed learning algorithm predicts new peptides having biological activities equivalent to the best of the training set and, in some cases, substantially improved activities. |
Introduction | By starting with a training set containing approximately 100 peptides with their corresponding validated bioactivity (binding affinity, IC50, etc), we expect that a state-of-the-art kernel method will give a bioactivity model which is sufficiently accurate to find new peptides with activities higher than the 100 used to learn the model. |
Introduction | Moreover, the proposed approach can be employed without known ligands for the target protein because it can leverage recent multi-target machine learning predictors [10, 14] where ligands for similar targets can serve as an initial training set . |
Simulation of a drug discovery | Correlation coefficient of hmndom predictions on the CAMPs data while varying R, the number of random peptides used as training set . |
The machine learning approach | For the sake of comparison, we would like to highlight that when fiq(y) = 1/ m, k = 1, UP = O, and ac = 0 the predictor hy(x) in Equation (6) reduces to predict the probability of sequence X given the position-specific weight matriX (PSWM) obtained from the training set . |